Insider Selling: Gyre Therapeutics, Inc. (NASDAQ:GYRE) Director Sells 3,452 Shares of Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) Director Nassim Usman sold 3,452 shares of Gyre Therapeutics stock in a transaction that occurred on Friday, June 28th. The stock was sold at an average price of $12.00, for a total value of $41,424.00. Following the completion of the transaction, the director now owns 1,636 shares of the company’s stock, valued at approximately $19,632. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Nassim Usman also recently made the following trade(s):

• On Wednesday, May 1st, Nassim Usman sold 20,000 shares of Gyre Therapeutics stock. The shares were sold at an average price of $14.13, for a total value of $282,600.00.

Gyre Therapeutics Stock Performance

GYRE opened at $11.72 on Thursday. The business has a fifty day moving average of $12.62 and a 200 day moving average of $16.62. Gyre Therapeutics, Inc. has a 52-week low of $4.80 and a 52-week high of $30.40.

Gyre Therapeutics (NASDAQ:GYRE) last posted its quarterly earnings data on Thursday, May 9th. The company reported $0.04 earnings per share (EPS) for the quarter. The business had revenue of $27.17 million for the quarter. On average, analysts expect that Gyre Therapeutics, Inc. will post -0.45 EPS for the current fiscal year.

About Gyre Therapeutics

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.